ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CEL Celadon Pharmaceuticals Plc

61.00
1.50 (2.52%)
22 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Celadon Pharmaceuticals Plc LSE:CEL London Ordinary Share GB00BDQYGP38 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.50 2.52% 61.00 57.00 65.00 61.00 59.50 59.50 12,246 14:00:11
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Investment Advice 149k -7.14M -0.1082 -5.64 39.26M

Pre Close Trading Update

23/03/2004 7:01am

UK Regulatory


RNS Number:8140W
Celsis International PLC
23 March 2004

CELSIS INTERNATIONAL PLC
Pre Close Trading Update

Celsis International plc, a leading international manufacturer of rapid
diagnostic systems for the world's pharmaceutical, personal care,dairy and
beverage industries and a leading US supplier of cGMP analytical services for
the pharmaceutical industry, announces an update on trading prior to the close
of the financial year.

The Group has made further progress across both divisions in the second half,
building on the successes of the first half.  As a result the Group is expected
to report profits in line with market expectations for the year ended 31st March
2004.

Jay LeCoque, Chief Executive Officer, Celsis Internationalplc commented:

"We are very encouraged with the progress Celsis is making.  The Product Group
continues its robust customer expansion and is performing well across all market
segments.  Our personal care and pharmaceutical testing systems continueto be
implemented around the world at a brisk pace.  Our dairy business is poised to
capture significant market share in all dairy-producing regions. The recent
Parmalat bankruptcy filing has not materially impacted our business and due to
our strict terms of payment, the Group had no significant exposure to bad debts
with any of Parmalat's subsidiaries across the world.

The Laboratory Group rebounded strongly in the fourth quarter, with revenues
from this period being the largest of the year.  We are confident that the
softness experienced during mid-year has passed and we expect the Laboratory
Group to grow at a faster and more profitable rate into our new fiscal year.

Margins across both divisions continue to improve and the current US dollar
situation has had no impact on our operations or profit performance.  We are
confident that we will shortly be in a position to announce further significant
orders."


                                                                   23 March 2004
Enquiries:

Celsis International plc                                   Tel: 01638 600 151
Jay LeCoque, Chief Executive Officer
Jenny Parsons, Corporate Communications

College Hill                                               Tel: 020 7457 2020
Nicholas Nelson
Corinna Dorward

Notes to editors

Celsis International plc

Celsis International plc is a world leader in the development and supply of
rapid diagnostic and monitoring systems to detect and measure microbial
contamination in finished products bound for consumers.  It has successfully
developed tests for use in the pharmaceutical, personal care & cosmetic, dairy
and beverage industries.  These tests are based upon years of research in enzyme
technology that employ numerous methods for the rapid detection of microbial
contamination.  Celsis International plc also has a leading laboratory services
company servicing the pharmaceutical and cosmetic and toiletries industries,
which operates primarily in the United States.

For further information on Celsis International plc visit www.celsis.com.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

TSTILFETVDIFFIS

1 Year Celadon Pharmaceuticals Chart

1 Year Celadon Pharmaceuticals Chart

1 Month Celadon Pharmaceuticals Chart

1 Month Celadon Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock